Interview: Setting The Course For Takeda’s R&D Future
Executive Summary
Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company's chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 18 months.
You may also be interested in...
Takeda's Deal Flurry Set To Wane
Takeda's reorganization and the focusing of its R&D on specialty medicines in three sectors is shifting to the next stage, with products moving through its pipeline; the company has lifted its financial outlook at the six-month stage, but is wary of the emergence of US generic competition to Velcade later this year.
Samsung Looks Beyond Biosimilars Via Takeda Tie-Up
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
Interview: Setting The Course For Takeda’s R&D Future (Part 2)
Dr. Andrew Plump joined Takeda from Sanofi in 2015 as the Japanese company’s chief medical and scientific officer. In his current position, based in the US, he leads the global R&D organization, which has seen much fundamental change over the past 12 months.